<DOC>
	<DOCNO>NCT01251731</DOCNO>
	<brief_summary>The purpose study evaluate single-dose ( SD ) pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety tolerability 10 , 40 , 80 mg E5501 follow select dose multiple dosing ( MD ) healthy Japanese , Chinese , Caucasian subject .</brief_summary>
	<brief_title>Single Multiple Dose Asian Bridging Study</brief_title>
	<detailed_description>This study evaluate single-dose ( SD ) pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety , tolerability oral dose 10 , 40 , 80 mg E5501 administer 36 healthy male female Japanese , Chinese , Caucasian subject . For SD Treatment Period , 12 subject ethnic group randomize receive single dos 10 , 40 , 80 mg E5501 match placebo treatment period . Each subject allocate treatment sequence dose either placebo three period dose three different dos three period . For Multiple-Dose ( MD ) Treatment Period 12 subject ethnic group randomize active ( dose level determine SD Treatment Period placebo 3:1 ratio .</detailed_description>
	<criteria>Key Normal healthy adult male female ( age 2045 year ) Body Mass Index great equal 18 less equal 29 time screen Japanese Chinese subject must bear respective country origin parent grandparent Japanese Chinese descent , respectively Japanese subject must live outside Japan 5 year ; Chinese subject must live outside China 10 year In addition mainland China , Chinese subject may Taiwan , Hong Kong , Mongolia Japanese Chinese subject must significantly change lifestyle regard diet ; i.e. , diet must significantly change since leave China Japan Platelet count 150,000 300,000/mm3 Key Evidence clinically significant cardiovascular , hepatic , gastrointestinal , renal , respiratory , endocrine , hematologic , neurologic , psychiatric disease abnormality know history gastrointestinal surgery could impact PK study drug Evidence organ dysfunction clinically significant deviation normal medical history , e.g. , history splenectomy History venous arterial thrombotic disease hypercoagulable state Hemoglobin level le 12.0 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>